Health Care/Hospital
Bioelectric Toothbrush Offers New Approach with 6x Plaque Removal
Clinically validated microcurrent technology now available in the U.S. market SAN FRANCISCO, Dec. 29, 2025 /PRNewswire/ -- Great Gums Inc. today announced the U.S. launch of its bioelectric toothbrush, a clinically validated oral care device that delivers safe microcurrents to remove plaque from ...
2025-12-29 21:00
298
HKSH Medical Group and Southern University of Science and Technology Collaborate for Medical and Medical Physics Training, Enhancing Medical Education and Research Innovation
HONG KONG, Dec. 29, 2025 /PRNewswire/ -- HKSH Medical Group ("HKSH") and Southern University of Science and Technology ("SUSTech") officially signed a Memorandum of Understanding ("MOU") on15 December 2025, a significant initiative to deepen collaboration betweenHong Kong and the Chinese Mainland...
2025-12-29 16:12
741
Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities
SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and more diverse therapeutic landscape. Viva Biotech has responded by building an integrated pharmacology pl...
2025-12-29 14:13
776
Alphamab Oncology Announces IND Application for a Phase II Clinical Study of HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 as First-line Treatment of Advanced Cervical Cancer was Officially Accepted by CDE
SUZHOU, China, Dec. 29, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immu...
2025-12-29 13:52
1189
Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy
TAIPEI and SAN DIEGO, Dec. 28, 2025 /PRNewswire/ -- Following its recent clinical collaboration with the multinational pharmaceutical company BeOne Medicines to explore combination therapy with its marketed PD-1 inhibitor in the challenging field of cold tumor treatment, Senhwa Biosciences, Inc. ...
2025-12-29 10:24
1022
Assure Healthcare Holdings Opens Second Clinic in Woodlands, Singapore
SINGAPORE, Dec. 29, 2025 /PRNewswire/ -- Assure Healthcare Holdings, a subsidiary of SingWealth Holdings, today announced the official opening of its second clinic,Assure Family Clinic Woodlands. This expansion marks the next phase in the Group's mission to make quality and comprehensive healthca...
2025-12-29 10:00
580
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a l...
2025-12-29 09:58
629
Festive Season Isolation: How Eczema Is Keeping Singaporeans From Gatherings
Medical Channel Asia's ongoing eczema survey reveals how chronic itch drives withdrawal, emotional strain, and missed celebrations during a period traditionally associated with connection and joy. SINGAPORE, Dec. 29, 2025 /PRNewswire/ -- For many, the festive season is marked by reunions, shared...
2025-12-29 08:30
454
CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596
SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted two separate Investigational New Drug (IND) applications to the National Medical Products Administr...
2025-12-29 08:10
437
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
- Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment - Accelerating R&D on core technologies, including expansion of indications for the Grabody platform SEOUL, South Korea, Dec. 26, 2025 /PRNewswire/ -- ABL Bio (CEO Sang Ho...
2025-12-26 12:55
1336
Arspura Showcases a New Standard for Healthy Kitchen Living at CES 2026
LOS ANGELES, Dec. 25, 2025 /PRNewswire/ -- From January 6–9, 2026, visitors can
experience Arspura'snext-generation range hoods
2025-12-26 01:30
540
Life-Space TrioBiotic Series Lands in Southeast Asia, Revolutionizing Gut Health with Triple-Action Formula
KUALA LUMPUR, Malaysia, Dec. 25, 2025 /PRNewswire/ -- A significant shift is underway in the regional health and wellness landscape as the innovative Life-Space TrioBiotic supplement series officially enters the Southeast Asian market. The launch introduces a cutting-edge "three-in-one" approach ...
2025-12-25 22:08
961
China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
* TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) colon cancer. * The TABOSUN® and TYVYT® c...
2025-12-25 16:45
857
Life-space's Patented Strain LPB27 Featured in Nature Supplement, Highlighting World-Class R&D Strength
KUALA LUMPUR, Malaysia, Dec. 25, 2025 /PRNewswire/ -- The Nature supplement highlights research exploring the potential ofLPB27 and Bifidobacterium breve 207-1 in supporting digestive and metabolic health. Both strains have already been successfully integrated into multiple Life-space products an...
2025-12-25 10:14
861
Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies
* Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management (CBL-0201WR Phase 2). * The study will evaluate CBL-514 in combination with Zepbound® (Eli Lilly) in...
2025-12-25 10:05
760
Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026
SYDNEY, Dec. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the acceptance of an ...
2025-12-24 22:02
699
Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study
SHANGHAI, Dec. 24, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance from the U.S. Food and Drug Administration (FDA) for its self-developed anti-ST2 monoclonal antibody (R&...
2025-12-24 22:00
904
HKSH Medical Group Signed Memorandum of Understanding with Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen To Advance Precision Proton Therapy, Furthering the Healthy China Initiative
HONG KONG, Dec. 24, 2025 /PRNewswire/ -- In alignment with the national framework for the advancement of proton therapy, facilitated by the National Cancer Center, HKSH Medical Group ("HKSH") and Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen ("Shenzhen Cancer Hospital") signed a me...
2025-12-24 15:49
1114
Hakka Medicine Goes Global: Jiaying Pharmaceutical Launches the Global Promotion Plan for Hakka Medicine in Hong Kong
HONG KONG, Dec. 24, 2025 /PRNewswire/ -- Recently, Guangdong Jiaying Pharmaceutical Co., Ltd. held the "First Hakka Medicine Historical and Cultural Symposium" and the "Jiaying Hakka Medicine - Double-ingredient Throat Wind Relief Powder Product Promotion Conference" inHong Kong SAR. Centered on ...
2025-12-24 10:00
1144
Nona Biosciences Expands Integrated Discovery-to-Clinical Capabilities Through Strategic Platform Growth
CAMBRIDGE, Mass., Dec. 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the expansion of its integrated discovery and development framework to support early clinical development an...
2025-12-24 09:20
1212
Week's Top Stories
Most Reposted
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 277 media titles]
2025-12-26 12:55Fijian and Chinese Scholars Gather to Discuss Bilateral Friendship and the Outlook for APEC 2026
[Picked up by 264 media titles]
2025-12-22 15:56
"Nihao China" App Launches as an All-in-One Solution for International Visitors
[Picked up by 253 media titles]
2025-12-24 17:54Sobot Shines in G2 Winter 2026: A New Benchmark in AI Customer Service
[Picked up by 252 media titles]
2025-12-24 10:00